EDRH
GRCE

Edmond de Rothschild Holding’s Grace Therapeutics GRCE Stock Holding History

Edmond de Rothschild Holding’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,083
Closed -$15K – 885
2022
Q1 		$15K Buy
+2,083
New +$14.9K ﹤0.01% 761
2021
Q4 		– Sell
-2,083
Closed -$25K – 910
2021
Q3 		$25K Hold
2,083
– – ﹤0.01% 735
2021
Q2 		$56K Hold
2,083
– – ﹤0.01% 671
2021
Q1 		$60K Buy
+2,083
New +$72.2K ﹤0.01% 610

Other funds holding GRCE

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SIAP
Sterling Investment Advisors (Pennsylvania) Berwyn, Pennsylvania $599M AUM 28.66% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Edmond de Rothschild Holding's GRCE Position: Q2 2022 in Review

Edmond de Rothschild Holding sold out of Grace Therapeutics (GRCE) in Q2 2022, closing a stake of 2,083 shares — an estimated $15K sold.

Edmond de Rothschild Holding first reported a position in GRCE in Q1 2021 and held it in 4 quarters. The position peaked at $60K in Q1 2021. 12 funds tracked by Wall St. Rank hold GRCE as of Q2 2022.

  • Edmond de Rothschild Holding reported no remaining Grace Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Edmond de Rothschild Holding sold 2,083 Grace Therapeutics shares in Q2 2022, an estimated $15K.
  • Edmond de Rothschild Holding first reported a position in Grace Therapeutics in Q1 2021 and held it in 4 quarters.
  • Edmond de Rothschild Holding's Grace Therapeutics position peaked at $60K in Q1 2021.
  • 12 funds tracked by Wall St. Rank held Grace Therapeutics as of Q2 2022.

Based on Edmond de Rothschild Holding's 13F filing for Q2 2022, filed 12 Aug 2022.